A Double-blind Non Inferiority Clinical Trial to Compare the Nephroprotection of Cilastatn Versus Thiosulfate in Patients Undergoing Debulking Surgery With Intraoperative Hyperthermic Intraperitoneal Chemotherapy With Cisplatin.

This study compares two kidney-protecting drugs — cilastatin versus thiosulfate — in women with ovarian cancer who are receiving a specialized treatment called HIPEC (hyperthermic intraperitoneal chemotherapy with cisplatin) during surgery. The goal is to find out which drug better protects the kidneys from cisplatin damage. **You may be eligible if...** - You are a woman between 18 and 75 years old - You have ovarian cancer confined to the abdomen and are eligible for cytoreductive surgery with HIPEC - Your general health is adequate for major surgery (normal or near-normal blood counts and organ function) - A multidisciplinary team has reviewed your case and determined HIPEC is appropriate **You may NOT be eligible if...** - You have cancer spread outside the abdomen (e.g., to the lungs or bones) - You are not medically fit for major surgery - Your general health score is poor (ECOG > 2) - You do not consent to participate Talk to your doctor to see if this trial is right for you.